Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.

RNAZ TransCode Therapeutics Inc

0,3802

0,0002 (0,05%)

Vor Marktöffnung

Zuletzt aktualisiert: 15:01:09

Verzögert um 15 Minuten

Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership

TransCode Therapeutics (NASDAQ:RNAZ)
Historical Stock Chart
Von Mär 2025 bis Apr 2025

Click Here for more TransCode Therapeutics Charts.

TransCode Therapeutics (NASDAQ:RNAZ)
Historical Stock Chart
Von Apr 2024 bis Apr 2025

Click Here for more TransCode Therapeutics Charts.

News TransCode Therapeutics Inc

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Montag 21 April 2025 (7 Tage vor) • Edgar (US Regulatory)

Form 8-K - Current report
Montag 21 April 2025 (7 Tage vor) • Edgar (US Regulatory)

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting
Montag 21 April 2025 (7 Tage vor) • PR Newswire (US)

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mittwoch 16 April 2025 (2 Wochen vor) • Edgar (US Regulatory)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Dienstag 15 April 2025 (2 Wochen vor) • Edgar (US Regulatory)

Form PRE 14A - Other preliminary proxy statements
Mittwoch 2 April 2025 (4 Wochen vor) • Edgar (US Regulatory)

Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Montag 31 März 2025 (4 Wochen vor) • Edgar (US Regulatory)

TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138
Donnerstag 27 März 2025 (1 Monat vor) • PR Newswire (US)

TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering
Dienstag 25 März 2025 (1 Monat vor) • PR Newswire (US)

Form 8-K - Current report
Dienstag 25 März 2025 (1 Monat vor) • Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Dienstag 25 März 2025 (1 Monat vor) • Edgar (US Regulatory)

TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Montag 24 März 2025 (1 Monat vor) • PR Newswire (US)

Weitere TransCode Therapeutics Inc News-Artikel

Deutsche Telekom

Financial Select Sector

Deutsche Lufthansa

Energy Select Sector SPDR

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen